Navigation Links
Pregabalin Proves Durable Pain Relief Option for Fibromyalgia

Pregabalin, typically used to treat nerve pain or seizures, appears to offer extended pain relief for those with fibromyalgia, according to research presented this week at// the American College of Rheumatology Annual Scientific Meeting in Washington, DC.

Fibromyalgia is an often misunderstood syndrome that causes widespread chronic muscle pain and tenderness in 2 percent of the U.S. population, most commonly women. In addition to pain, fibromyalgia is often associated with fatigue, sleep disturbances and memory problems. Unfortunately, to date, no FDA-approved treatment has been available for this syndrome.

Researchers enrolled 1,051 participants in a six-week program of 300, 450 or 600 mg daily doses of pregabalin to optimize pain control and medication tolerance. On average, the population was 93% female, 88% white, had endured fibromyalgia for over seven years and measured their pain severity as 78 on a 100 point scale.

At the end of the 6-week program, 663 participants (63%) cited over 50% reduction in pain, and being “much” or “very much improved.” Of these, 566 were randomized into a 26-week double-blind study to receive either pregabalin at the optimal dosage established during the 6 weeks prior or placebo. The primary goal of this six-month study, one of the longest control studies conducted to date, was to determine how long their therapeutic responses lasted.

One-fourth of placebo-treated patients saw worsening by day 7 as compared to day 34 for those on medication. By the end of the double-blind treatment, nearly twice (61%) as many placebo patients had lost response as compared to 32% of the patients on medication. The most common side effects of pregabalin were dizziness, somnolence, sinusitis, joint pain and anxiety. One death occurred each in the placebo and treatment arms of the trial, but neither was treatment-related.

“Fibromyalgia is a common and often debilitating pain syndrome,” expl ains Leslie J. Crofford, MD, Gloria W. Singletary Professor of Rheumatology & Women’s Health, University of Kentucky, Lexington, Kentucky, and an investigator in the study. “The results of this six-month study indicate pregabalin has a significant benefit in terms of longer-term pain relief for these patients.”


Related medicine news :

1. ZD1839 Proves Effective - A Breakthrough in fighting Lung Cancer
2. Study Proves That MMR Vaccine Is Not Connected To Autistic Babies
3. Pilot Study Proves Home Abortions ‘Safe’
4. Many Nonprescription Cough Medicines Proves Ineffective
5. Less Invasive By Pass Surgery Proves Economical In The Long Run
6. Epidural Mistakes Proves To Be Fatal Blunders
7. Combined Anti-Fever Drug Therapy Proves Unsafe for Childhood Fever
8. Drug Trial Proves Nightmare for British Indian Student
9. Naturopathic Care Proves Beneficial for TMD Pain
10. Medtronic Device Proves Effective in Parkinson’s Diseas
11. Large Community Spirometry Screening Proves Successful
Post Your Comments:

(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding ... of its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. ... James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. ...
(Date:6/25/2016)... ... 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the ... to iHire in recognition of their exemplary accomplishments in worksite health promotion. , The ... Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... To deal with these feelings, many turn to unhealthy avenues, such as drug or ... Center of Marne, Michigan, has released tools for healthy coping following a traumatic event. ...
(Date:6/24/2016)... Texas (PRWEB) , ... June 24, 2016 , ... ... International Conference and Scientific Sessions in Dallas that it will receive two significant ... of the grants came as PHA marked its 25th anniversary by recognizing patients, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA ... the Road To Recovery® program to drive cancer patients to and from their cancer ... ensure the highest quality of life and ongoing independence. Getting to and from ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Research and Markets has announced the addition ... - Forecast to 2022" report to their offering. ... to date financial data derived from varied research sources to ... potential impact on the market during the next five years, ... of sub markets, regional and country level analysis. The report ...
(Date:6/23/2016)... Research and Markets has announced the ... report to their offering. ... favourable commercial environment for MedImmune to enter. The US ageing ... serve to drive considerable growth for effective anti-influenza medications. The ... sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... , June 23, 2016 , ... on Thursday, July 7, 2016 , , , , LOCATION: ... , , , , EXPERT PANELISTS:  , , , ... Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and ... The global pharmaceutical industry is witnessing an exceptional era. ...
Breaking Medicine Technology: